Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate SLE in NZM 2328 mice

BACKGROUND/OBJECTIVE: Treatment with immune checkpoint inhibitors (ICIs) in oncology patients is increasing. Although ICIs trigger rheumatic immune-related adverse events, development of SLE features has been rare. Whether long-term treatment with ICIs would promote SLE features remains unknown. To...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Lupus Sci Med
Glavni autori: Stohl, William, Yu, Ning, Chalmers, Samantha A, Putterman, Chaim, Jacob, Chaim O
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2019
Teme:
Brief Communication
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6519407/
https://ncbi.nlm.nih.gov/pubmed/31168399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/lupus-2018-000313
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items